MannKind Corporation has named former Acorda Therapeutics COO Lauren Sabella as Executive VP, Chief Operating Officer. Sabella’s experience includes 12 years at Acorda, first as Chief Commercial Officer and then as COO; she previously served in a number of roles at Boehringer Ingelheim, including as Executive Director of Marketing for the Respiratory Franchise and as VP of Sales.
In January 2023, MannKind announced that it would advance MNKD-101 clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung infections to a Phase 2/3 study. The company is also conducting a Phase 3 trial of its Afrezza insulin DPI in patients aged 4-17, with plans to seek an expansion of the indication for pediatric use.
Sabella said, “I am honored and excited to be joining MannKind as it continues to scale and execute its plan to help people living with endocrine and orphan lung diseases. I am energized to work with this innovative team as we drive operational excellence in an action-driven environment.”
MannKind CEO Michael Castagna commented, “Lauren is an inspirational leader, and we are delighted to welcome her to MannKind at a pivotal time. Lauren will be leading all our critical functions that operate in Danbury, focused on growing our endocrine business and preparing to launch our emerging pipeline in the orphan lung area.”
Read the MannKind Corporation press release.
